Exton-based Immunome has reported positive results from testing its antibody cocktail against live versions of the omicron variant of COVID-19. John George broke through the breakthrough for the Philadelphia Business Journal.

According to Immunome CEO Purnanand Sarma, there has been a marked reduction in the number of antibody therapeutics that are active against omicron under emergency use authorization. That trend shows there is a “clear, immediate need” for the continued advancement of novel therapeutic approaches, he said.

The company’s three-antibody cocktail, known as IMM-BCP-01, has an independent mechanism of anti-viral activity that provides a differentiated way to fight variants of SARS-CoV-2. Immunome believes that its experimental therapy is less susceptible to variant drift (small changes in a virus) than other treatments.

Live virus testing of the antibody cocktail was conducted at Boston University’s National Emerging Infectious Diseases Laboratories and at Washington University.

The company now plans to continue to advance its experimental therapy into a phase-1b clinical trial.

The news sent the business’s stock up by eight percent to $9.12 per share on Tuesday before dropping by three percent to land at $8.20 per share later in the day.

Read more about Immunome in the Philadelphia Business Journal.